Keywords: denosumab, increases, bmd, adt, patients, biotechnology, major
Denosumab increases BMD in ADT patients
Article | 21 July 2008
US biotechnology major Amgen says its drug candidate denosumab can prevent bone loss in men undergoing androgen-deprivation therapy for non-metastatic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
